What is Medrhythms?
Medrhythms is dedicated to advancing neurotherapeutics through its proprietary Rhythmic Auditory Stimulation (RAS) technology platform. This innovative approach combines music, sensors, and software to enhance motor function and rehabilitation for patients suffering from neurologic injuries and walking disabilities. By offering personalized digital therapeutics supported by an extensive music library, Medrhythms aims to significantly improve the quality of life and independence for those affected by gait disorders worldwide.
How much funding has Medrhythms raised?
Medrhythms has raised a total of $35.6M across 3 funding rounds:
Series A
$5.3M
Series B
$27M
Private Equity
$3.3M
Series A (2018): $5.3M with participation from Peter J. Werth and Jean Hoffman
Series B (2021): $27M led by Werth Family Investment Associates, Global Brain, Morningside Venture Capital, Advantage Capital, and Bose Ventures
Private Equity (2026): $3.3M, investors not publicly disclosed
Key Investors in Medrhythms
Global Brain
Global Brain is an independent venture capital firm that specializes in supporting startups to achieve global success through hands-on assistance and collaboration with large corporations. With over $2.3 billion in assets under management, the firm actively invests in more than 100 startups annually, focusing on various sectors including technology, healthcare, and education. Their services include fundraising support, strategic consulting, and career guidance for individuals interested in the startup ecosystem. Global Brain aims to foster innovation and bring new industries to society by leveraging its extensive network and expertise.
Morningside Venture Capital
Morningside Venture Capital, headquartered in Hong Kong, and established in 1986, is a private equity and venture capital firm specializing in early-stage technology company investments.
Advantage Capital
Advantage Capital Partners operates as a venture capital firm. The Company invests in cleantech, communication, energy, information technology, and life sciences industries. Advantage Capital Partners is located in New Orleans.
What's next for Medrhythms?
The substantial enterprise-level funding secured by Medrhythms positions the company for accelerated growth and further development of its neurotherapeutic solutions. This strategic investment is expected to fuel advancements in their RAS technology, expand market reach, and potentially lead to new clinical applications. The company's focus on transforming patient care through digital therapeutics suggests a trajectory towards becoming a leader in the digital health and neurorehabilitation sectors, with potential for further strategic partnerships and market penetration.
See full Medrhythms company page
